Otros idiomas Y-mAbs Therapeutics, Inc.

Acciones

YMAB

US9842411095

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
14,71 ^USD	-0,88 %		-2,78 %	+115,69 %

14/03	El director financiero de Y-mAbs Therapeutics, Bo Kruse, dimitirá	MT
14/03	Y-mAbs Therapeutics, Inc. anuncia la dimisión de Bo Kruse como vicepresidente ejecutivo, secretario y tesorero, con efecto a partir del 31 de julio de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	26/04
Y-mAbs to Present at 2024 ASCO Annual Meeting	25/04
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	14/03
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	14/03
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	14/03
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	14/03
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	04/03
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	04/03
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	04/03
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	01/03
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	29/02
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	29/02
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	29/02
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024	16/02
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	02/01
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	22/12
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index	18/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Y-mAbs Therapeutics, Inc.

Acciones

YMAB

US9842411095

Otros idiomas

Filtros